Medical DevicesTechnology

Gastric Bypass Edges Lap-band and Sleeve Gastrectomy in Outcomes

1 Mins read

Two recent reports in the Archives of Surgery (Arch Surg. 2011;146[2]:143-148, 149-155) indicate that, in the treatment of moderately to morbidly obese patients, while gastric bypass surgery has a comparable rate of complications as lap-band and sleeve gastrectomy, it has a lower rate of re-operations needed, results in better long-term weight loss and better outcomes associated with type 2 diabetes. Although the authors of the two studies are careful to note that additional research is necessary to both confirm these results and elucidate the reasons behind the different outcomes, the lowered risk of complications combined with better apparent outcomes will temper the rate of adoption of lap-band usage that was poised to accelerate as a result of the FDA’s recent decision to expand the use of lap-band for patients with lower body mass indices (BMI). Obesity is the subject of intense focus, in clinical practice and medical technology, since it carries high costs in the healthcare systems, directly and indirectly (through co-morbidities like diabetes and heart disease, among many others). Treatment of obesity now includes a range of medical and surgical options:

  • Drugs
    • Satiety
    • Malabsorption
    • Appetite suppression
    • Combination drugs
  • Medical devices
    • Restrictive
    • Artificial fullness
    • Malabsorption
    • Gastric emptying
    • Appetite suppression

For more information on obesity treatment markets, see MedMarket Diligence, LLC, Report #S835, “Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019” (published February 2011).

183 posts

About author
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses. Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.
Related posts

Eco-Friendly Practice: How Hospitals Can Adapt To Protect The Planet

3 Mins read
Hospitals around the world are busier than ever before. Every health care facility requires a significant amount of energy to operate effectively….
Medical InnovationsSpecialtiesTechnology

Deciphering the Controversy of Adipose Derived Stem Cells in the Context of Healthcare

4 Mins read
As we enter a new era of medical advancements, several new techniques in medicine have been pioneered. You may have heard of…
Medical InnovationsTechnology

5 AI Hotspots In Medicine To Know About

3 Mins read
Medicine moves slowly — until it doesn’t. Sometimes, a technology like CRISPR comes along that changes the treatment landscape for dozens of…